Zydus Launches REVAHALE™, Positioning It as India's First Once-Daily Nebulised LAMA for COPD
Ahmedabad, India (August 10, 2026) - Zydus Lifesciences Limited has launched REVAHALE™ (Revefenacin), establishing it as the first once-daily nebulised Long-Acting Muscarinic Antagonist (LAMA) available in India. The drug is indicated for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD).REVAHALE™ represents a significant advancement, being the sole LAMA in India that combines sustained 24-hour bronchodilation with nebulized administration. This offering provides a new therapeutic option for COPD patients requiring nebulised therapy.
The medication is designed to deliver sustained bronchdilation over 24 hours through once-daily dosing. It addresses critical challenges faced by certain COPD patients, including those with severe respiratory impairment or who experience difficulties utilizing handheld inhalers and generating sufficient inspiratory effort for effective drug delivery.
By providing a convenient nebulised delivery platform, REVAHALE™ reduces dependence on inhalation technique and inspiratory flow. The therapy is compatible with standard jet nebulisers, ensuring ease of use for both patients and caregivers. Clinical studies have demonstrated that the medication offers significant and sustained improvements in lung function for patients diagnosed with moderate to very severe COPD while maintaining a favorable safety profile.
Zydus Lifesciences Limited noted that COPD remains a major public health issue in India, serving as a leading cause of morbidity and mortality. While inhaled bronchodilator therapies have substantially improved disease management, the need for solutions addressing patient compliance and delivery methods persists.
REVAHALE™ is engineered to meet these unmet needs by combining once-daily administration with compatibility with standard jet nebulisers, providing a differentiated maintenance treatment option in COPD care.
ZYDUSLIFE Stock Price Movement
Zydus Lifesciences Limited shares closed higher today after gaining 0.43% to settle at ₹1119. The stock saw robust trading activity during the session, with a total volume of 904,023 shares recorded.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.